About this trial
The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Men aged 18 to 60 years with a clinical diagnosis of androgenetic alopecia ;
Participants who use an acceptable contraceptive method, or who declare that their partner uses an acceptable contraceptive method, according to the protocol, and who agree to use it throughout the study period.
Disqualifiers
History of allergic reactions to any of the active ingredients or to any of the ingredients of teh formulation;
Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years;
Participants with conditions that may affect hair growth or with underlying conditions that cause hair loss, such as a diagnosis of alopecia areata, fibrosing or cicatricial alopecia, or telogen effluvium, the latter being present at the time of screening;
Participants with concomitant inflammation or other dermatological conditions of the scalp, such as moderate or severe psoriasis or seborrheic dermatitis, and/or active infection and/or keloid formation in the area of alopecia;
Trial design
Parallel
Treatments tested in this trial
APSMNF 1
DrugAdminister twice a day during 24 weeks.
APSMNF 2
DrugAdminister twice a day during 24 weeks.
Eniagor®
DrugAdminister twice a day during 24 weeks.
Treatment groups
Trial outcomes
Primary outcomes
Variation in hair density assessed by phototrichogram.
Secondary outcomes
Adverse events incidence and classification
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: